Open AccessTargeting CD22 for the Treatment of B-Cell Malignancies
Author(s) -
Nikesh Shah,
Lubomir Sokol
Publication year - 2021
Publication title -
immunotargets and therapy
Language(s) - English
Resource type - Journals
ISSN - 2253-1556
DOI - 10.2147/itt.s288546
Subject(s) - cd22 , chimeric antigen receptor , cd19 , cancer research , b cell , monoclonal antibody , immunology , antibody , medicine , antigen , antibody drug conjugate , radioimmunotherapy , immunotoxin , t cell , immune system
Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surface sialoglycoprotein uniquely present on B-cells and regulates B-cell function and proliferation. Thus, it is an appealing therapeutic target for autoimmune disorders and B-cell malignancies. A variety of therapies targeting CD22 have been developed, including monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, chimeric antigen receptor T cells, and bispecific antibodies. Here, we review the biology of CD22 and key therapies targeting CD22 in lymphoid malignancies.